Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Disease
- Therapeutic
- Arthritis
- Pain
- Ulcer
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 240458
License Grant
The Taiwan Licensee obtained from the Taiwan Licensor the global rights to BEL-DLS01, an API intended to treat inflammatory bowel diseases, and its surrounding proprietary information and platforms to develop, modify, manufacture, distribute and sell pharmaceutical products.
License Property
Investigational drugs that are designed for the treatment of autoimmune diseases, including BLI-1006 to treat inflammatory bowel disease.
Field of Use
With BEL-DLS01 as the API, the Taiwan Licensee is developing BLI-1006 to treat inflammatory bowel disease.
IPSCIO Record ID: 256652
License Grant
The Taiwan Licensor granted Licensee the global rights to use our proprietary technology, data and intellectual property of Licensor’s project BLI-1006 to develop and commercialize the therapeutic treatment for inflammatory bowel disease.
Field of Use
This agreement pertains to the drug industry.
IPSCIO Record ID: 240440
License Grant
The Taiwan Licensee obtained from the Taiwan Licensor the exclusive global rights to PDC-1421, an API, and its surrounding proprietary information to develop, manufacture, distribute and sell pharmaceutical products for potential use in major depressive disorders.
License Property
PDC-1421, an API for possible use in major depressive disorder with Montgomery-Asberg Depression Rating Scale.
Field of Use
With PDC-1421 as the API, the Licensee is developing two new drug candidates, BLI-1005 to treat MDD and BLI-1008 for ADHD.
Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations. It is often accompanied by low self-esteem, loss of interest in normally enjoyable activities, low energy, and pain without a clear cause.
Attention deficit hyperactivity disorder (ADHD) is a mental health disorder that can cause above-normal levels of hyperactive and impulsive behaviors. People with ADHD may also have trouble focusing their attention on a single task or sitting still for long periods of time. Both adults and children can have ADHD.
IPSCIO Record ID: 240459
License Grant
The Taiwan Licensor granted the Taiwan Licensee non-exclusive licensing rights to use, modify and manufacture BEL-DLS03, an API designed to treat rheumatoid arthritis, and its analysis platform for therapeutic and dietary purposes. In accordance with the Licensor BLI-1007 License Agreement and its Amendment, in 2016 the License became an exclusive licensing right to use patent of BEL-DLS03 and the manufacturing method.
License Property
BEL-DLS03 Patent, an API designed to treat rheumatoid arthritis, and its analysis platform for therapeutic and dietary purposes.
Field of Use
The Licensee was conducting preclinical studies of BEL-DLS03, which is the API for drug candidate BLI-1007 for Rheumatoid Arthritis.
IPSCIO Record ID: 269165
License Grant
The Irish Company licenses certain rights to Amitiza to an undisclosed third party in exchange for royalties on net sales of the product.
License Property
Amitiza includes niche specialty generic drugs products, active pharmaceutical ingredients ('API(s)') and Amitiza® (lubiprostone) ('Amitiza').
Licensor develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics.
Field of Use
Amitiza is medication used to treat certain types of constipation (chronic idiopathic constipation, irritable bowel syndrome with constipation). Chronic idiopathic constipation has an unknown cause and is not due to diet, other diseases, or drugs.
IPSCIO Record ID: 372413
License Grant
The Licensor Parties grant an exclusive, world-wide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under Patent Rights and Technical information, to the extent not prohibited by other patents, in the Field of Use.
License Property
The Licensor Parties are the owners of the Method Patent and a pending patent entitled Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists and one Licensor is the owner/Sponsor of IBD FDA IND#, FDA orphan drug designation x-2969 and a pending patent for Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists.
Field of Use
The term Field of Use means development, production, use, and storage of Licensed Products, alone or in combination with other treatments, for the prevention and/or treatment of Crohn's disease and other inflammatory and ulcerative diseases of the bowel.
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus
IPSCIO Record ID: 27157
License Grant
The Swedish Company granted and Licensee obtained licenses, and options for licenses, to make, have made, use and sell in the Territory under Licensed Patents, Technical Information and Trademarks certain pharmaceutical compounds which the Company (or any of its Affiliates) has developed or acquired and certain other pharmaceutical compounds. Group C Compounds shall mean the Compounds rofleponide, remacemide, candesartan cilexetil, perprazole H199/18 , budesonide for the treatment of inflammatory bowel disease in humans (K50-51) and ropivacaine for the treatment of inflammatory bowel disease in humans.
Field of Use
The rights granted apply to humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
